目次

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 34)
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 STUDY SCOPE
1.3.1 LIQUID BIOPSY MARKET
1.3.2 REGIONAL SCOPE
1.3.3 YEARS CONSIDERED
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 40)
2.1 RESEARCH DATA
2.2 RESEARCH APPROACH
FIGURE 1 LIQUID BIOPSY MARKET: RESEARCH DESIGN METHODOLOGY
2.2.1 SECONDARY DATA
2.2.1.1 Key data from secondary sources
2.2.2 PRIMARY DATA
2.2.2.1 Primary sources
2.2.2.2 Key data from primary sources
2.2.2.3 Key industry insights
2.2.2.4 Breakdown of primary interviews
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.3 MARKET SIZE ESTIMATION
2.3.1 BOTTOM-UP APPROACH
2.3.1.1 Approach 1: Company revenue estimation approach
FIGURE 4 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
2.3.1.2 Approach 2: Presentations of companies and primary interviews
2.3.1.3 CAGR projections
FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
2.3.2 TOP-DOWN APPROACH
FIGURE 6 LIQUID BIOPSY MARKET: TOP-DOWN APPROACH
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 7 DATA TRIANGULATION METHODOLOGY
2.5 MARKET SHARE
2.6 STUDY ASSUMPTIONS
2.7 GROWTH RATE ASSUMPTIONS
2.8 RISK ASSESSMENT
2.8.1 RISK ASSESSMENT: LIQUID BIOPSY MARKET

3 EXECUTIVE SUMMARY (Page No. - 52)
FIGURE 8 LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2022 VS. 2027 (USD MILLION)
FIGURE 9 MARKET, BY CIRCULATING BIOMARKER, 2022 VS. 2027 (USD MILLION)
FIGURE 10 MARKET, BY TECHNOLOGY, 2022 VS. 2027 (USD MILLION)
FIGURE 11 MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION)
FIGURE 12 MARKET, BY CLINICAL APPLICATION, 2022 VS. 2027 (USD MILLION)
FIGURE 13 MARKET, BY SAMPLE TYPE, 2022 VS. 2027 (USD MILLION)
FIGURE 14 MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)
FIGURE 15 MARKET, BY REGION, 2022 VS. 2027 (USD MILLION)

4 PREMIUM INSIGHTS (Page No. - 58)
4.1 MARKET OVERVIEW
FIGURE 16 RISING INCIDENCE OF CANCER TO DRIVE GROWTH IN LIQUID BIOPSY MARKET
4.2 MARKET SHARE, BY PRODUCT & SERVICE, 2022 VS. 2027
FIGURE 17 ASSAY KITS TO CONTINUE TO DOMINATE LIQUID BIOPSY MARKET DURING FORECAST PERIOD
4.3 MARKET SHARE, BY CIRCULATING BIOMARKER, 2022 VS. 2027
FIGURE 18 CIRCULATING TUMOR CELLS TO CONTINUE TO DOMINATE MARKET IN 2027
4.4 MARKET SHARE, BY CLINICAL APPLICATION, 2022 VS. 2027
FIGURE 19 THERAPY SELECTION SEGMENT TO HOLD LARGEST SHARE OF MARKET DURING FORECAST PERIOD
4.5 MARKET SHARE, BY TECHNOLOGY, 2022 VS. 2027
FIGURE 20 MULTI-GENE PARALLEL ANALYSIS USING NGS SEGMENT TO HOLD LARGER SHARE OF MARKET IN 2027
4.6 MARKET SHARE, BY APPLICATION, 2022 VS. 2027
FIGURE 21 CANCER APPLICATIONS TO LEAD MARKET IN 2027
4.7 MARKET SHARE, BY SAMPLE TYPE, 2022 VS. 2027
FIGURE 22 BLOOD TYPE SEGMENT TO CONTINUE TO DOMINATE MARKET IN 2027
4.8 MARKET SHARE, BY END USER, 2022 VS. 2027
FIGURE 23 REFERENCE LABORATORIES TO DRIVE MARKET GROWTH IN 2027
4.9 MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 24 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE IN LIQUID BIOPSY MARKET DURING FORECAST PERIOD

5 MARKET OVERVIEW (Page No. - 63)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 25 MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Rising incidence and prevalence of cancer
TABLE 1 NUMBER OF PREVALENT CANCER CASES WORLDWIDE IN 2020, BY TYPE OF CANCER
5.2.1.2 Cancer awareness initiatives undertaken by global health organizations
5.2.1.3 Increasing preference for non-invasive treatment procedures
5.2.2 RESTRAINTS
5.2.2.1 Lower sensitivity of certain liquid biopsy procedures
5.2.3 OPPORTUNITIES
5.2.3.1 Growing significance of companion diagnostics
5.2.3.2 Growth opportunities in emerging countries
5.2.4 CHALLENGES
5.2.4.1 Unclear reimbursement scenario
5.3 PRICING ANALYSIS
TABLE 2 AVERAGE SELLING PRICES OF KEY PLAYERS, BY PRODUCT
TABLE 3 AVERAGE SELLING PRICE TREND
5.4 PATENT ANALYSIS
FIGURE 26 PATENT ANALYSIS OF LIQUID BIOPSY
TABLE 4 PATENT ANALYSIS
5.5 VALUE CHAIN ANALYSIS
FIGURE 27 MAJOR VALUE ADDITION DURING MANUFACTURING & ASSEMBLY PHASE
5.6 SUPPLY CHAIN ANALYSIS
FIGURE 28 MARKET: SUPPLY CHAIN ANALYSIS
5.7 ECOSYSTEM ANALYSIS OF MARKET
FIGURE 29 MARKET: ECOSYSTEM ANALYSIS
5.7.1 MARKET: ROLE IN ECOSYSTEM
5.8 PORTER’S FIVE FORCES ANALYSIS
TABLE 5 MARKET: PORTER’S FIVE FORCES ANALYSIS
5.8.1 THREAT FROM NEW ENTRANTS
5.8.2 THREAT FROM SUBSTITUTES
5.8.3 BARGAINING POWER OF BUYERS
5.8.4 BARGAINING POWER OF SUPPLIERS
5.8.5 DEGREE OF COMPETITION
5.9 REGULATORY LANDSCAPE
5.9.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 6 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 7 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 8 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 9 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 10 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.9.2 NORTH AMERICA
5.9.2.1 US
5.9.2.2 Canada
5.9.3 EUROPE
5.9.4 ASIA PACIFIC
5.9.4.1 China
5.9.4.2 Japan
5.9.5 LATIN AMERICA
5.9.5.1 Brazil
5.9.5.2 Mexico
5.9.6 MIDDLE EAST
5.9.7 AFRICA
5.10 TECHNOLOGY ANALYSIS
5.11 PESTLE ANALYSIS
5.12 TRADE ANALYSIS
5.12.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS
5.12.1.1 Export scenario for liquid biopsy
TABLE 11 EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2017-2021 (USD MILLION)
5.12.1.2 Import scenario for liquid biopsy
TABLE 12 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2017-2021 (USD MILLION)
TABLE 13 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2017-2021 (TONS)
5.13 KEY CONFERENCES AND EVENTS IN 2022-2023
TABLE 14 MARKET: DETAILED LIST OF CONFERENCES AND EVENTS
5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.14.1 REVENUE SHIFT & REVENUE POCKETS FOR LIQUID BIOPSY PRODUCT MANUFACTURERS
FIGURE 30 REVENUE SHIFT FOR LIQUID BIOPSY MARKET
5.15 KEY STAKEHOLDERS AND BUYING CRITERIA
5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 31 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF LIQUID BIOPSY PRODUCTS & SERVICES
TABLE 15 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF LIQUID BIOPSY PRODUCTS & SERVICES
5.15.2 BUYING CRITERIA
FIGURE 32 KEY BUYING CRITERIA FOR LIQUID BIOPSY PRODUCTS & SERVICES
TABLE 16 KEY BUYING CRITERIA FOR LIQUID BIOPSY PRODUCTS & SERVICES
5.16 CASE STUDY ANALYSIS
5.16.1 CASE STUDY 1
5.16.2 CASE STUDY 2

6 LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE (Page No. - 90)
6.1 INTRODUCTION
TABLE 17 MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
6.2 ASSAY KITS
6.2.1 RECURRENT REQUIREMENT AND PURCHASES OF ASSAY KITS TO DRIVE GROWTH
TABLE 18 KEY PRODUCTS IN ASSAY KITS MARKET
TABLE 19 LIQUID BIOPSY ASSAY KITS MARKET, BY REGION, 2020-2027 (USD MILLION)
6.3 INSTRUMENTS
6.3.1 LATEST ADVANCEMENTS IN PCR TECHNOLOGIES TO ENSURE MARKET GROWTH
TABLE 20 KEY PRODUCTS IN INSTRUMENTS MARKET
TABLE 21 LIQUID BIOPSY INSTRUMENTS MARKET, BY REGION, 2020-2027 (USD MILLION)
6.4 SERVICES
6.4.1 INCREASING NUMBER OF LIQUID BIOPSY-BASED SERVICE DEVELOPMENTS TO SUPPORT MARKET GROWTH
TABLE 22 LIQUID BIOPSY SERVICES MARKET, BY REGION, 2020-2027 (USD MILLION)

7 LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER (Page No. - 96)
7.1 INTRODUCTION
TABLE 23 MARKET, BY CIRCULATING BIOMARKER, 2020-2027 (USD MILLION)
7.2 CIRCULATING TUMOR CELLS (CTC)
7.2.1 EASY COLLECTION AND PERSISTENT ASSESSMENT & ANALYSIS OF OVERALL TUMOR BURDEN TO DRIVE DEMAND
TABLE 24 MARKET FOR CIRCULATING TUMOR CELLS, BY REGION, 2020-2027 (USD MILLION)
7.3 CIRCULATING TUMOR DNA (CTDNA)
7.3.1 ABILITY OF CTDNA ANALYSIS TO SIGNIFICANTLY IMPROVE TUMOR DIAGNOSIS TO DRIVE MARKET
TABLE 25 MARKET FOR CIRCULATING TUMOR DNA, BY REGION, 2020-2027 (USD MILLION)
7.4 CELL-FREE DNA (CFDNA)
7.4.1 GROWING APPLICATION OF CFDNA IN PRENATAL SCREENING TO DRIVE GROWTH
TABLE 26 MARKET FOR CELL-FREE DNA, BY REGION, 2020-2027 (USD MILLION)
7.5 EXTRACELLULAR VESICLES (EVS)
7.5.1 ABILITY TO REMAIN STABLE IN BLOOD CIRCULATION OVER OTHER ANALYTES TO ENSURE CONSISTENT GROWTH IN MARKET
TABLE 27 LIQUID BIOPSY - MARKET FOR EXTRACELLULAR VESICLES, BY REGION, 2020-2027 (USD MILLION)
7.6 OTHER CIRCULATING BIOMARKERS
TABLE 28 LIQUID BIOPSY - MARKET FOR OTHER CIRCULATING BIOMARKERS, BY REGION, 2020-2027 (USD MILLION)

8 LIQUID BIOPSY MARKET, BY TECHNOLOGY (Page No. - 102)
8.1 INTRODUCTION
TABLE 29 MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
8.2 MULTI-GENE PARALLEL ANALYSIS USING NGS
8.2.1 HIGH SENSITIVITY AND ECONOMICAL BENEFITS TO DRIVE GROWTH
TABLE 30 MARKET FOR MULTI-GENE PARALLEL ANALYSIS USING NGS, BY REGION, 2020-2027 (USD MILLION)
8.3 SINGLE-GENE ANALYSIS USING PCR MICROARRAYS
8.3.1 COST BENEFITS OF PCR TECHNOLOGY TO DRIVE ADOPTION
TABLE 31 MARKET FOR SINGLE-GENE ANALYSIS USING PCR MICROARRAYS, BY REGION, 2020-2027 (USD MILLION)

9 LIQUID BIOPSY MARKET, BY APPLICATION (Page No. - 106)
9.1 INTRODUCTION
TABLE 32 MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
9.2 CANCER APPLICATIONS
TABLE 33 GLOBAL CANCER INCIDENCE, 2020 VS. 2040 (MILLION)
TABLE 34 LIQUID BIOPSY - MARKET FOR CANCER APPLICATIONS, BY REGION, 2020-2027 (USD MILLION)
TABLE 35 LIQUID BIOPSY - MARKET FOR CANCER APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION)
9.2.1 LUNG CANCER
9.2.1.1 Growing prevalence of lung cancer to propel market growth
TABLE 36 GLOBAL LUNG CANCER INCIDENCE, 2020 VS. 2040
TABLE 37 LIQUID BIOPSY - MARKET FOR LUNG CANCER, BY REGION, 2020-2027 (USD MILLION)
9.2.2 BREAST CANCER
9.2.2.1 Increasing government funding for breast cancer research to spur growth
TABLE 38 GLOBAL BREAST CANCER INCIDENCE, 2020 VS. 2040
TABLE 39 LIQUID BIOPSY -?MARKET FOR BREAST CANCER, BY REGION, 2020-2027 (USD MILLION)
9.2.3 COLORECTAL CANCER
9.2.3.1 Rising prevalence of colorectal cancer to propel market
TABLE 40 GLOBAL COLORECTAL CANCER INCIDENCE, 2020 VS. 2040
TABLE 41 LIQUID BIOPSY -?MARKET FOR COLORECTAL CANCER, BY REGION, 2020-2027 (USD MILLION)
9.2.4 PROSTATE CANCER
9.2.4.1 Growing number of prostate cancer patients to support market growth
TABLE 42 GLOBAL PROSTATE CANCER INCIDENCE, 2020 VS. 2040
TABLE 43 LIQUID BIOPSY -?MARKET FOR PROSTATE CANCER, BY REGION, 2020-2027 (USD MILLION)
9.2.5 MELANOMA
9.2.5.1 Growing need for early diagnosis of genetically mutated tumors to drive market growth
TABLE 44 GLOBAL MELANOMA INCIDENCE, 2020 VS. 2040
TABLE 45 LIQUID BIOPSY - MARKET FOR MELANOMA, BY REGION, 2020-2027 (USD MILLION)
9.2.6 OTHER CANCERS
TABLE 46 GLOBAL INCIDENCE OF OTHER CANCERS, 2020
TABLE 47 LIQUID BIOPSY - MARKET FOR OTHER CANCERS, BY REGION, 2020-2027 (USD MILLION)
9.3 NON-CANCER APPLICATIONS
TABLE 48 LIQUID BIOPSY - MARKET FOR NON-CANCER APPLICATIONS, BY REGION, 2020-2027 (USD MILLION)
TABLE 49 LIQUID BIOPSY - MARKET FOR NON-CANCER APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION)
9.3.1 NON-INVASIVE PRENATAL TESTING (NIPT)
9.3.1.1 Growing demand for NIPT in high-risk pregnancies to drive growth
TABLE 50 LIQUID BIOPSY - MARKET FOR NIPT, BY REGION, 2020-2027 (USD MILLION)
9.3.2 ORGAN TRANSPLANTATIONS
9.3.2.1 Need for early detection of rejection to improve survival chances to drive growth
TABLE 51 LIQUID BIOPSY - MARKET FOR ORGAN TRANSPLANTATIONS, BY REGION, 2020-2027 (USD MILLION)
9.3.3 INFECTIOUS DISEASE TESTING
9.3.3.1 Potential to reliably identify a wide variety of infections to drive adoption
TABLE 52 LIQUID BIOPSY - MARKET FOR INFECTIOUS DISEASE TESTING, BY REGION, 2020-2027 (USD MILLION)

10 LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION (Page No. - 122)
10.1 INTRODUCTION
TABLE 53 MARKET, BY CLINICAL APPLICATION, 2020-2027 (USD MILLION)
10.2 THERAPY SELECTION
10.2.1 GROWING PREFERENCE DUE TO NON-INVASIVENESS OF LIQUID BIOPSY TESTS TO DRIVE GROWTH
TABLE 54 MARKET FOR THERAPY SELECTION, BY REGION, 2020-2027 (USD MILLION)
10.3 TREATMENT MONITORING
10.3.1 ABILITY TO QUANTITATIVELY CALCULATE CONCENTRATIONS OF CANCER-RELATED MUTATIONS TO FUEL DEMAND
TABLE 55 MARKET FOR TREATMENT MONITORING, BY REGION, 2020-2027 (USD MILLION)
10.4 RECURRENCE MONITORING
10.4.1 ABILITY TO DETECT CANCER MUTATIONS THROUGH CTDNA TO DRIVE GROWTH
TABLE 56 MARKET FOR RECURRENCE MONITORING, BY REGION, 2020-2027 (USD MILLION)
10.5 EARLY CANCER SCREENING
10.5.1 POTENTIAL OF LIQUID BIOPSY TO DETECT CANCER IN EARLY STAGES TO DRIVE MARKET
TABLE 57 LIQUID BIOPSY - MARKET FOR EARLY CANCER SCREENING, BY REGION, 2020-2027 (USD MILLION)

11 LIQUID BIOPSY MARKET, BY SAMPLE TYPE (Page No. - 128)
11.1 INTRODUCTION
TABLE 58 MARKET, BY SAMPLE TYPE, 2020-2027 (USD MILLION)
TABLE 59 LIQUID BIOPSY SAMPLES AND APPLICATIONS
11.2 BLOOD
11.2.1 SIMPLE AND NON-INVASIVE NATURE TO DRIVE MARKET GROWTH
TABLE 60 LIQUID BIOPSY - MARKET FOR BLOOD SAMPLES, BY REGION, 2020-2027 (USD MILLION)
11.3 OTHER SAMPLE TYPES
TABLE 61 LIQUID BIOPSY - MARKET FOR OTHER SAMPLE TYPES, BY REGION, 2020-2027 (USD MILLION)

12 LIQUID BIOPSY MARKET, BY END USER (Page No. - 132)
12.1 INTRODUCTION
TABLE 62 MARKET, BY END USER, 2020-2027 (USD MILLION)
12.2 REFERENCE LABORATORIES
12.2.1 INCREASING OUTSOURCING OF LIQUID BIOPSY TESTS TO REFERENCE LABORATORIES TO DRIVE GROWTH
TABLE 63 LIQUID BIOPSY - MARKET FOR REFERENCE LABORATORIES, BY REGION, 2020-2027 (USD MILLION)
12.3 HOSPITALS AND PHYSICIAN LABORATORIES
12.3.1 GROWING NUMBER OF HOSPITALS WORLDWIDE TO BOOST GROWTH
TABLE 64 LIQUID BIOPSY - MARKET FOR HOSPITALS AND PHYSICIAN LABORATORIES, BY REGION, 2020-2027 (USD MILLION)
12.4 ACADEMIC & RESEARCH CENTERS
12.4.1 GROWING FOCUS OF RESEARCH FOR DEVELOPMENT OF INNOVATIVE LIQUID BIOPSY TESTS TO FUEL GROWTH
TABLE 65 LIQUID BIOPSY - MARKET FOR ACADEMIC & RESEARCH CENTERS, BY REGION, 2020-2027 (USD MILLION)
12.5 OTHER END USERS
TABLE 66 LIQUID BIOPSY -?MARKET FOR OTHER END USERS, BY REGION, 2020-2027 (USD MILLION)

13 LIQUID BIOPSY MARKET, BY REGION (Page No. - 137)
13.1 INTRODUCTION
TABLE 67 MARKET, BY REGION, 2020-2027 (USD MILLION)
13.2 NORTH AMERICA
TABLE 68 NORTH AMERICA: NUMBER OF NEW CANCER CASES, BY TYPE OF CANCER, 2020
FIGURE 33 NORTH AMERICA: MARKET SNAPSHOT
TABLE 69 NORTH AMERICA: MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
TABLE 70 NORTH AMERICA: MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
TABLE 71 NORTH AMERICA: MARKET, BY CIRCULATING BIOMARKER, 2020-2027 (USD MILLION)
TABLE 72 NORTH AMERICA: MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
TABLE 73 NORTH AMERICA: MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 74 NORTH AMERICA: MARKET, BY CLINICAL APPLICATION, 2020-2027 (USD MILLION)
TABLE 75 NORTH AMERICA: MARKET, BY SAMPLE TYPE, 2020-2027 (USD MILLION)
TABLE 76 NORTH AMERICA: LIQUID BIOPSY - MARKET, BY END USER, 2020-2027 (USD MILLION)
13.2.1 US
13.2.1.1 Increasing prevalence of cancer to drive growth
TABLE 77 US: MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
TABLE 78 US: MARKET, BY CIRCULATING BIOMARKER, 2020-2027 (USD MILLION)
TABLE 79 US: MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
TABLE 80 US: MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 81 US: MARKET, BY CLINICAL APPLICATION, 2020-2027 (USD MILLION)
TABLE 82 US: MARKET, BY SAMPLE TYPE, 2020-2027 (USD MILLION)
TABLE 83 US: LIQUID BIOPSY MARKET, BY END USER, 2020-2027 (USD MILLION)
13.2.2 CANADA
13.2.2.1 Availability of various cancer screening programs to drive growth
TABLE 84 CANADA: MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
TABLE 85 CANADA: MARKET, BY CIRCULATING BIOMARKER, 2020-2027 (USD MILLION)
TABLE 86 CANADA: MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
TABLE 87 CANADA: MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 88 CANADA: MARKET, BY CLINICAL APPLICATION, 2020-2027 (USD MILLION)
TABLE 89 CANADA: MARKET, BY SAMPLE TYPE, 2020-2027 (USD MILLION)
TABLE 90 CANADA: LIQUID BIOPSY MARKET, BY END USER, 2020-2027 (USD MILLION)
13.3 EUROPE
TABLE 91 EUROPE: MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
TABLE 92 EUROPE: MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
TABLE 93 EUROPE: MARKET, BY CIRCULATING BIOMARKER, 2020-2027 (USD MILLION)
TABLE 94 EUROPE: MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
TABLE 95 EUROPE: MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 96 EUROPE: MARKET, BY CLINICAL APPLICATION, 2020-2027 (USD MILLION)
TABLE 97 EUROPE: MARKET, BY SAMPLE TYPE, 2020-2027 (USD MILLION)
TABLE 98 EUROPE: LIQUID BIOPSY MARKET, BY END USER, 2020-2027 (USD MILLION)
13.3.1 GERMANY
13.3.1.1 Favorable government health policies to support market growth
TABLE 99 GERMANY: MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
TABLE 100 GERMANY: MARKET, BY CIRCULATING BIOMARKER, 2020-2027 (USD MILLION)
TABLE 101 GERMANY: MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
TABLE 102 GERMANY: MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 103 GERMANY: MARKET, BY CLINICAL APPLICATION, 2020-2027 (USD MILLION)
TABLE 104 GERMANY: MARKET, BY SAMPLE TYPE, 2020-2027 (USD MILLION)
TABLE 105 GERMANY: LIQUID BIOPSY MARKET, BY END USER, 2020-2027 (USD MILLION)
13.3.2 UK
13.3.2.1 Increasing number of diagnostic laboratories to propel market growth
TABLE 106 UK: MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
TABLE 107 UK: MARKET, BY CIRCULATING BIOMARKER, 2020-2027 (USD MILLION)
TABLE 108 UK: MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
TABLE 109 UK: MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 110 UK: MARKET, BY CLINICAL APPLICATION, 2020-2027 (USD MILLION)
TABLE 111 UK: MARKET, BY SAMPLE TYPE, 2020-2027 (USD MILLION)
TABLE 112 UK: LIQUID BIOPSY MARKET, BY END USER, 2020-2027 (USD MILLION)
13.3.3 FRANCE
13.3.3.1 Rising R&D expenditure to drive market growth
TABLE 113 FRANCE: MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
TABLE 114 FRANCE: MARKET, BY CIRCULATING BIOMARKER, 2020-2027 (USD MILLION)
TABLE 115 FRANCE: MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
TABLE 116 FRANCE: MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 117 FRANCE: MARKET, BY CLINICAL APPLICATION, 2020-2027 (USD MILLION)
TABLE 118 FRANCE: MARKET, BY SAMPLE TYPE, 2020-2027 (USD MILLION)
TABLE 119 FRANCE: LIQUID BIOPSY MARKET, BY END USER, 2020-2027 (USD MILLION)
13.3.4 ITALY
13.3.4.1 Growing research on discovery of novel circulating cancer biomarkers to drive market growth
TABLE 120 ITALY: MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
TABLE 121 ITALY: MARKET, BY CIRCULATING BIOMARKER, 2020-2027 (USD MILLION)
TABLE 122 ITALY: MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
TABLE 123 ITALY: MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 124 ITALY: MARKET, BY CLINICAL APPLICATION, 2020-2027 (USD MILLION)
TABLE 125 ITALY: MARKET, BY SAMPLE TYPE, 2020-2027 (USD MILLION)
TABLE 126 ITALY: LIQUID BIOPSY MARKET, BY END USER, 2020-2027 (USD MILLION)
13.3.5 SPAIN
13.3.5.1 Growing focus on personalized medicine to support market growth
TABLE 127 SPAIN: MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
TABLE 128 SPAIN: MARKET, BY CIRCULATING BIOMARKER, 2020-2027 (USD MILLION)
TABLE 129 SPAIN: MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
TABLE 130 SPAIN: MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 131 SPAIN: MARKET, BY CLINICAL APPLICATION, 2020-2027 (USD MILLION)
TABLE 132 SPAIN: MARKET, BY SAMPLE TYPE, 2020-2027 (USD MILLION)
TABLE 133 SPAIN: MARKET, BY END USER, 2020-2027 (USD MILLION)
13.3.6 REST OF EUROPE
TABLE 134 REST OF EUROPE: MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
TABLE 135 REST OF EUROPE: MARKET, BY CIRCULATING BIOMARKER, 2020-2027 (USD MILLION)
TABLE 136 REST OF EUROPE: MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
TABLE 137 REST OF EUROPE: MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 138 REST OF EUROPE: MARKET, BY CLINICAL APPLICATION, 2020-2027 (USD MILLION)
TABLE 139 REST OF EUROPE: MARKET, BY SAMPLE TYPE, 2020-2027 (USD MILLION)
TABLE 140 REST OF EUROPE: LIQUID BIOPSY MARKET, BY END USER, 2020-2027 (USD MILLION)
13.4 ASIA PACIFIC
FIGURE 34 ASIA PACIFIC: MARKET SNAPSHOT
TABLE 141 ASIA PACIFIC: MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
TABLE 142 ASIA PACIFIC: MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
TABLE 143 ASIA PACIFIC: MARKET, BY CIRCULATING BIOMARKER, 2020-2027 (USD MILLION)
TABLE 144 ASIA PACIFIC: MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
TABLE 145 ASIA PACIFIC: MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 146 ASIA PACIFIC: MARKET, BY CLINICAL APPLICATION, 2020-2027 (USD MILLION)
TABLE 147 ASIA PACIFIC: MARKET, BY SAMPLE TYPE, 2020-2027 (USD MILLION)
TABLE 148 ASIA PACIFIC: LIQUID BIOPSY MARKET, BY END USER, 2020-2027 (USD MILLION)
13.4.1 CHINA
13.4.1.1 Growing public access to advanced healthcare facilities to drive market
TABLE 149 CHINA: MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
TABLE 150 CHINA: MARKET, BY CIRCULATING BIOMARKER, 2020-2027 (USD MILLION)
TABLE 151 CHINA: MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
TABLE 152 CHINA: MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 153 CHINA: MARKET, BY CLINICAL APPLICATION, 2020-2027 (USD MILLION)
TABLE 154 CHINA: MARKET, BY SAMPLE TYPE, 2020-2027 (USD MILLION)
TABLE 155 CHINA: LIQUID BIOPSY MARKET, BY END USER, 2020-2027 (USD MILLION)
13.4.2 JAPAN
13.4.2.1 Universal healthcare reimbursement policy to fuel growth
TABLE 156 JAPAN: MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
TABLE 157 JAPAN: MARKET, BY CIRCULATING BIOMARKER, 2020-2027 (USD MILLION)
TABLE 158 JAPAN: MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
TABLE 159 JAPAN: MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 160 JAPAN: MARKET, BY CLINICAL APPLICATION, 2020-2027 (USD MILLION)
TABLE 161 JAPAN: MARKET, BY SAMPLE TYPE, 2020-2027 (USD MILLION)
TABLE 162 JAPAN: MARKET, BY END USER, 2020-2027 (USD MILLION)
13.4.3 INDIA
13.4.3.1 Increasing private & public investments in healthcare system to boost market
TABLE 163 INDIA: MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
TABLE 164 INDIA: MARKET, BY CIRCULATING BIOMARKER, 2020-2027 (USD MILLION)
TABLE 165 INDIA: MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
TABLE 166 INDIA: MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 167 INDIA: MARKET, BY CLINICAL APPLICATION, 2020-2027 (USD MILLION)
TABLE 168 INDIA: MARKET, BY SAMPLE TYPE, 2020-2027 (USD MILLION)
TABLE 169 INDIA: LIQUID BIOPSY MARKET, BY END USER, 2020-2027 (USD MILLION)
13.4.4 REST OF ASIA PACIFIC
TABLE 170 REST OF ASIA PACIFIC: MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
TABLE 171 REST OF ASIA PACIFIC: MARKET, BY CIRCULATING BIOMARKER, 2020-2027 (USD MILLION)
TABLE 172 REST OF ASIA PACIFIC: MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
TABLE 173 REST OF ASIA PACIFIC: MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 174 REST OF ASIA PACIFIC: MARKET, BY CLINICAL APPLICATION, 2020-2027 (USD MILLION)
TABLE 175 REST OF ASIA PACIFIC: MARKET, BY SAMPLE TYPE, 2020-2027 (USD MILLION)
TABLE 176 REST OF ASIA PACIFIC: LIQUID BIOPSY MARKET, BY END USER, 2020-2027 (USD MILLION)
13.5 LATIN AMERICA
13.5.1 INCREASING PRIVATE & PUBLIC INVESTMENTS TO DRIVE MARKET
TABLE 177 LATIN AMERICA: MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
TABLE 178 LATIN AMERICA: MARKET, BY CIRCULATING BIOMARKER, 2020-2027 (USD MILLION)
TABLE 179 LATIN AMERICA: MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
TABLE 180 LATIN AMERICA: MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 181 LATIN AMERICA: MARKET, BY CLINICAL APPLICATION, 2020-2027 (USD MILLION)
TABLE 182 LATIN AMERICA: MARKET, BY SAMPLE TYPE, 2020-2027 (USD MILLION)
TABLE 183 LATIN AMERICA: LIQUID BIOPSY MARKET, BY END USER, 2020-2027 (USD MILLION)
13.6 MIDDLE EAST & AFRICA
13.6.1 INCREASING FUNDING IN RESEARCH TO DRIVE MARKET GROWTH
TABLE 184 MIDDLE EAST & AFRICA: MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
TABLE 185 MIDDLE EAST & AFRICA: MARKET, BY CIRCULATING BIOMARKER, 2020-2027 (USD MILLION)
TABLE 186 MIDDLE EAST & AFRICA: MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
TABLE 187 MIDDLE EAST & AFRICA: MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 188 MIDDLE EAST & AFRICA: MARKET, BY CLINICAL APPLICATION, 2020-2027 (USD MILLION)
TABLE 189 MIDDLE EAST & AFRICA: MARKET, BY SAMPLE TYPE, 2020-2027 (USD MILLION)
TABLE 190 MIDDLE EAST & AFRICA: LIQUID BIOPSY MARKET, BY END USER, 2020-2027 (USD MILLION)

14 COMPETITIVE LANDSCAPE (Page No. - 195)
14.1 OVERVIEW
14.2 STRATEGIES OF KEY PLAYERS
14.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN LIQUID BIOPSY MARKET
TABLE 191 OVERVIEW OF STRATEGIES DEPLOYED BY KEY LIQUID BIOPSY COMPANIES
14.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
FIGURE 35 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN LIQUID BIOPSY MARKET
14.4 MARKET SHARE ANALYSIS
14.4.1 LIQUID BIOPSY MARKET
FIGURE 36 MARKET SHARE, BY KEY PLAYER (2021)
TABLE 192 MARKET SHARE: DEGREE OF COMPETITION
14.5 COMPANY EVALUATION QUADRANT
14.5.1 LIST OF EVALUATED VENDORS
14.5.2 STARS
14.5.3 EMERGING LEADERS
14.5.4 PERVASIVE PLAYERS
14.5.5 PARTICIPANTS
FIGURE 37 MARKET: COMPETITIVE LEADERSHIP MAPPING, 2021
14.6 COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES (2021)
14.6.1 PROGRESSIVE COMPANIES
14.6.2 STARTING BLOCKS
14.6.3 RESPONSIVE COMPANIES
14.6.4 DYNAMIC COMPANIES
FIGURE 38 MARKET: COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES, 2021
14.7 COMPETITIVE BENCHMARKING
14.7.1 PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS
FIGURE 39 PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS OF TOP PLAYERS IN LIQUID BIOPSY MARKET
TABLE 193 MARKET: COMPANY GEOGRAPHICAL FOOTPRINT
TABLE 194 MARKET: COMPANY PRODUCT & SERVICE FOOTPRINT
TABLE 195 MARKET: DETAILED LIST OF KEY START-UPS/SMES
14.8 COMPETITIVE SCENARIO
14.8.1 PRODUCT LAUNCHES & APPROVALS
TABLE 196 KEY PRODUCT LAUNCHES & APPROVALS
14.8.2 DEALS
TABLE 197 KEY DEALS

15 COMPANY PROFILES (Page No. - 208)
(Business overview, Products offered, Recent Developments, MNM view)*
15.1 KEY PLAYERS
15.1.1 QIAGEN N.V.
TABLE 198 QIAGEN N.V.: BUSINESS OVERVIEW
FIGURE 40 QIAGEN N.V.: COMPANY SNAPSHOT (2021)
15.1.2 F. HOFFMANN-LA ROCHE AG
TABLE 199 F. HOFFMANN-LA ROCHE AG: BUSINESS OVERVIEW
FIGURE 41 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT (2021)
15.1.3 MYRIAD GENETICS, INC.
TABLE 200 MYRIAD GENETICS, INC.: BUSINESS OVERVIEW
FIGURE 42 MYRIAD GENETICS, INC.: COMPANY SNAPSHOT (2021)
15.1.4 THERMO FISHER SCIENTIFIC, INC.
TABLE 201 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW
FIGURE 43 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2021)
15.1.5 GUARDANT HEALTH, INC.
TABLE 202 GUARDANT HEALTH, INC.: BUSINESS OVERVIEW
FIGURE 44 GUARDANT HEALTH, INC.: COMPANY SNAPSHOT (2021)
15.1.6 BIO-RAD LABORATORIES, INC.
TABLE 203 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
FIGURE 45 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2021)
15.1.7 ILLUMINA, INC.
TABLE 204 ILLUMINA, INC.: BUSINESS OVERVIEW
FIGURE 46 ILLUMINA, INC.: COMPANY SNAPSHOT (2021)
15.1.8 EXACT SCIENCES CORPORATION
TABLE 205 EXACT SCIENCES CORPORATION: BUSINESS OVERVIEW
FIGURE 47 EXACT SCIENCES CORPORATION: COMPANY SNAPSHOT (2021)
15.1.9 SYSMEX INOSTICS (SUBSIDIARY OF SYSMEX CORPORATION)
TABLE 206 SYSMEX INOSTICS: BUSINESS OVERVIEW
FIGURE 48 SYSMEX CORPORATION: COMPANY SNAPSHOT (2021)
15.1.10 BIOCEPT, INC.
TABLE 207 BIOCEPT, INC.: BUSINESS OVERVIEW
FIGURE 49 BIOCEPT, INC.: COMPANY SNAPSHOT (2021)
15.1.11 MDXHEALTH
TABLE 208 MDXHEALTH: BUSINESS OVERVIEW
FIGURE 50 MDXHEALTH: COMPANY SNAPSHOT (2021)
15.2 OTHER PLAYERS
15.2.1 NEOGENOMICS, INC.
15.2.2 EPIGENOMICS AG
15.2.3 ANGLE PLC
15.2.4 MENARINI-SILICON BIOSYSTEMS
15.2.5 VORTEX BIOSCIENCES, INC.
15.2.6 EXOSOME DIAGNOSTICS, INC.
15.2.7 MEDGENOME INC.
15.2.8 AGENA BIOSCIENCE, INC.
15.2.9 PERSONAL GENOME DIAGNOSTICS, INC.
15.2.10 FREENOME HOLDINGS, INC.
15.2.11 STRAND LIFE SCIENCES
15.2.12 LUNGLIFE AI, INC.
15.2.13 LUCENCE HEALTH INC.
15.2.14 ANPAC BIO-MEDICAL SCIENCE CO., LTD.

*Details on Business overview, Products offered, Recent Developments, MNM view might not be captured in case of unlisted companies.

16 APPENDIX (Page No. - 263)
16.1 DISCUSSION GUIDE
16.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
16.3 CUSTOMIZATION OPTIONS
16.4 RELATED REPORTS
16.5 AUTHOR DETAILS